{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:13:22Z","timestamp":1761596002036,"version":"3.37.3"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T00:00:00Z","timestamp":1493251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HLA"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Highly immunized patients are a challenge for organ transplantation programs. One way of increasing the likelihood of transplantation in this group of patients is to expand the possible donations by defining acceptable <jats:styled-content style=\"fixed-case\">HLA<\/jats:styled-content> mismatches. In the Scandiatransplant Acceptable Mismatch Program (<jats:styled-content style=\"fixed-case\">STAMP<\/jats:styled-content>), a de\u2010centralized approach has been implemented in 2009.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>The program has been improved during the years from utilizing <jats:styled-content style=\"fixed-case\">HLA<\/jats:styled-content>\u2010A, \u2010B, \u2010<jats:styled-content style=\"fixed-case\">DR<\/jats:styled-content> matching only to include typing of all deceased donors for <jats:styled-content style=\"fixed-case\">HLA<\/jats:styled-content>\u2010A, \u2010B, \u2010C, \u2010<jats:styled-content style=\"fixed-case\">DRB1<\/jats:styled-content> and \u2010<jats:styled-content style=\"fixed-case\">DQB1<\/jats:styled-content>. The calculation of a transplantability score (<jats:styled-content style=\"fixed-case\">TS<\/jats:styled-content>) has been introduced in order to take both <jats:styled-content style=\"fixed-case\">HLA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">AB0<\/jats:styled-content> into consideration resulting in a more realistic picture of the transplantability chance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Patients were selected for eligibility and results of immunisation status were prepared in each of the 9 tissue typing laboratories, while access to the program is finally governed by a common steering group of immunologists and clinicians.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the period from March 2009 until February 2015, 96 patients were transplanted within this program. The mean recipient age was 49 years and 57% were females, 30% of the patients were first transplants and of these 93% were females. The majority of the patients had 2\u20105 <jats:styled-content style=\"fixed-case\">HLA<\/jats:styled-content>\u2010A, \u2010B. \u2010<jats:styled-content style=\"fixed-case\">DR<\/jats:styled-content> mismatches. The allograft survival at 60 months was 79.1%. Applying the <jats:styled-content style=\"fixed-case\">TS<\/jats:styled-content> to the cohort confirmed that patients with a low <jats:styled-content style=\"fixed-case\">TS<\/jats:styled-content> score had longer waiting times.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The program has matured during the years and now proves to be a valid approach for transplanting highly immunized patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tan.13046","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T21:04:05Z","timestamp":1493327045000},"page":"17-24","source":"Crossref","is-referenced-by-count":3,"title":["Scandiatransplant acceptable mismatch program (STAMP) a bridge to transplanting highly immunized patients"],"prefix":"10.1111","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-3334","authenticated-orcid":false,"given":"P.","family":"Koefoed\u2010Nielsen","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Weinreich","sequence":"additional","affiliation":[{"name":"Scandiatransplant office  Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bengtsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Rudbeck Laboratory Uppsala University Hospital  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lauronen","sequence":"additional","affiliation":[{"name":"Finnish Red Cross Blood Service  Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Naper","sequence":"additional","affiliation":[{"name":"Department of Immunology and Transfusion Medicine Oslo University Hospital  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"G\u00e4bel","sequence":"additional","affiliation":[{"name":"Sahlgrenska University Hospital Institute of Transplantation  Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. S.","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Department of Nephrology University Hospital of Copenhagen, Rigshospitalet  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Wennberg","sequence":"additional","affiliation":[{"name":"Department of Transplantation Surgery Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. V.","family":"Reis\u00e6ter","sequence":"additional","affiliation":[{"name":"Department of Transplantation Medicine Oslo University Hospital, Rikshospitalet  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. K.","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the Nordic Kidney group and the Tissue Typing group in Scandiatransplant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,4,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(66)92829-7"},{"key":"e_1_2_6_3_1","unstructured":"Scandiatransplant.http:\/\/www.scandiatransplant.org\/resources\/dias2015_2.pdfslide 23."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr429"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2012.01543.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009101065"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03985.x"},{"key":"e_1_2_6_8_1","article-title":"Inflammation in early kidney allograft surveillance biopsies with and without associated tubulointerstitial chronic damage as a predictor of fibrosis progression and development of de novo donor specific antibodies","author":"Garcia\u2010Carro C","year":"2016","journal-title":"Transplantation"},{"key":"e_1_2_6_9_1","unstructured":"Scandiatransplant ttm.http:\/\/www.scandiatransplant.org\/members\/stamp\/STAMP13TTmeet.pdfslide no.2."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2015.08.006"},{"key":"e_1_2_6_11_1","unstructured":"UNOS allocation scheme.https:\/\/optn.transplant.hrsa.gov\/media\/1200\/optn_policies.pdf#nameddest=Policy_08."},{"key":"e_1_2_6_12_1","unstructured":"UNOS KAS.https:\/\/optn.transplant.hrsa.gov\/media\/1178\/kas_report_06\u20102015.pdf."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2012.10.010"},{"key":"e_1_2_6_14_1","unstructured":"Scandiatransplant STAMP manual.http:\/\/scandiatransplant.org\/organ\u2010allocation\/manual_STAMP.pdf."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2010.10.013"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e328365b3b9"},{"key":"e_1_2_6_17_1","unstructured":"genovis.http:\/\/www.genovis.com\/fabricator."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31822872dd"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000315"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13295"}],"container-title":["HLA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftan.13046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tan.13046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T15:22:14Z","timestamp":1696173734000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tan.13046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,27]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1111\/tan.13046"],"URL":"https:\/\/doi.org\/10.1111\/tan.13046","archive":["Portico"],"relation":{},"ISSN":["2059-2302","2059-2310"],"issn-type":[{"type":"print","value":"2059-2302"},{"type":"electronic","value":"2059-2310"}],"subject":[],"published":{"date-parts":[[2017,4,27]]}}}